Amgen (AMG 337)
M&A
STATUS
Buyout/LBO
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
A mid-stage anticancer MET inhibitor drug. The compound is a phase 2 small molecule inhibitor of the cell surface enzyme which stimulates cancer cell scattering, invasion and protection from apoptosis. It is being developed to treat gastric and esophageal cancers.
Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- One Amgen Center Drive
- Thousand Oaks, CA 91320
- United States
Amgen (AMG 337) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Amgen (AMG 337)‘s full profile, request access.
Request full access to PitchBookAmgen (AMG 337) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Amgen (AMG 337)‘s full profile, request access.
Request full access to PitchBook